Keeping Track: Lilly's Olaratumab, Cempra's Solithromycin, AAA's Lutathera Complete Submissions; End Of The Road For Rociletinib
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: Shutdown Edition
The latest drug development news and highlights from our US FDA Performance Tracker.
Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas
Accelerated filing was supported by trial of patients with 25 subtypes of soft tissue sarcoma and confirmatory study will span 50 kinds.
Keeping Track: Amgen Parsabiv Is Latest To Receive Complete Response; Pfizer Troxyca ER Finally Approved; Remune Returns
The latest drug development news and highlights from our FDA Performance Tracker.